21世纪以来胃癌治疗进展及未来展望

doi:10.19401/j.cnki.1007-3639.2024.03.001

摘要/Abstract

摘要：

胃癌作为中国发病率及死亡率均位居前列的恶性肿瘤，具有异质性高、预后差等特点。进入21世纪，随着基因组学、腹腔镜微创技术、靶向治疗及免疫治疗的迅速发展，胃癌诊疗水平取得了长足进步。本文总结21世纪以来胃癌防治领域中的重要研究进展，并对未来进行展望，期待在胃癌早期筛查、诊断和精准治疗方面取得更大进步和突破，进一步提高患者的总生存率，将胃癌转变为可以控制的“慢性病”。

关键词: 胃癌, 微创治疗, 肿瘤分期, D2根治术, 围手术期治疗, 靶向治疗, 免疫治疗, 进展, 展望

Abstract:

Gastric cancer, a malignant tumor with high morbidity and mortality in China, has characteristics such as high heterogeneity and poor prognosis. With the advent of the 21st century, significant progress has been made in gastric cancer diagnosis and treatment due to the rapid development of genomics, laparoscopic minimally invasive techniques, targeted therapy and immunotherapy. This article summarized the important research progress in the field of gastric cancer prevention and treatment since the 21st century, and looked forward to the future. We hope to make greater progress and breakthroughs in early screening, diagnosis and precise treatment of gastric cancer, further improve the overall survival rate of patients, and transform gastric cancer into a controllable “chronic disease”.

Key words: Gastric cancer, Minimally invasive treatment, Tumor staging, D2 radical surgery, Perioperative treatment, Targeted therapy, Immunotherapy, Progress, Prospect

中图分类号:

许永虎, 徐大志. 21世纪以来胃癌治疗进展及未来展望[J]. 中国癌症杂志, 2024, 34(3): 239-249.

XU Yonghu, XU Dazhi. Progress and prospects of gastric cancer treatment in the 21st century[J]. China Oncology, 2024, 34(3): 239-249.

图/表 1

参考文献 68

[1]	郑荣寿, 张思维, 孙可欣, 等. 2016年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2023, 45(3): 212-220.
	ZHENG R S, ZHANG S W, SUN K X, et al. Cancer statistics in China, 2016[J]. Chin J Oncol, 2023, 45(3): 212-220.
[2]	DENOIX P. Ongoing investigation in cancer centers[J]. Bull Inst Natl Hyg, 1946, 1: 12-7. pmid: 20986738
[3]	吴怀申, 何雍毅. 恶性肿瘤的TNM分类法[J]. 癌症, 1999(1): 104-105.
	WU H S, HE Y Y. TNM classification of malignant tumors[J]. Chin J Cancer, 1999(1): 104-105.
[4]	RAMI-PORTA R. Future perspectives on the TNM Staging for lung cancer[J]. Cancers (Basel), 2021, 13(8): 1940.
[5]	日本胃癌学会. 胃癌处理规约[M]. 1版. 东京: 金原出版株式会社, 1962.
	Japanese Gastric Cancer Association. Gastric cancer management protocol[M]. 1 edition. Tokyo: Kanehara Publishing Co., LTD, 1962.
[6]	日本胃癌学会. 胃癌处理规约[M]. 14版. 东京: 金原出版株式会社, 2010.
	Japanese Gastric Cancer Association. Gastric cancer management protocol[M]. 14 edition. Tokyo: Kanehara Publishing Co., LTD, 2010.
[7]	CUSCHIERI A, WEEDEN S, FIELDING J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group[J]. Br J Cancer, 1999, 79(9/10): 1522-1530. doi: 10.1038/sj.bjc.6690243
[8]	BONENKAMP J J, HERMANS J, SASAKO M, et al. Extended lymph-node dissection for gastric cancer[J]. N Engl J Med, 1999, 340(12): 908-914. doi: 10.1056/NEJM199903253401202
[9]	SONGUN I, PUTTER H, KRANENBARG E M, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial[J]. Lancet Oncol, 2010, 11(5): 439-449. doi: 10.1016/S1470-2045(10)70070-X pmid: 20409751
[10]	SASAKO M, SANO T, YAMAMOTO S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer[J]. N Engl J Med, 2008, 359(5): 453-462. doi: 10.1056/NEJMoa0707035
[11]	MACDONALD J S, SMALLEY S R, BENEDETTI J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction[J]. N Engl J Med, 2001, 345(10): 725-730. doi: 10.1056/NEJMoa010187
[12]	CUNNINGHAM D, ALLUM W H, STENNING S P, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med, 2006, 355(1): 11-20. doi: 10.1056/NEJMoa055531
[13]	AL-BATRAN S E, HOMANN N, PAULIGK C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial[J]. Lancet, 2019, 393(10184): 1948-1957. doi: 10.1016/S0140-6736(18)32557-1
[14]	KANG Y K, KIM H D, YOOK J H, et al. Neoadjuvant docetaxel, oxaliplatin, and s-1 plus surgery and adjuvant s-1 for resectable advanced gastric cancer: final survival outcomes of the randomized phase 3 PRODIGY trial[J]. J Clin Oncol, 2023, 41(16_suppl): 4067.
[15]	ZHANG X T, LIANG H, LI Z Y, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial[J]. Lancet Oncol, 2021, 22(8): 1081-1092. doi: 10.1016/S1470-2045(21)00297-7
[16]	IWASAKI Y, TERASHIMA M, MIZUSAWA J, et al. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial[J]. Gastric Cancer, 2021, 24(2): 492-502. doi: 10.1007/s10120-020-01136-7 pmid: 33200303
[17]	SAKURAMOTO S, SASAKO M, YAMAGUCHI T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine[J]. N Engl J Med, 2007, 357(18): 1810-1820. doi: 10.1056/NEJMoa072252
[18]	SASAKO M, SAKURAMOTO S, KATAI H, et al. Five-year outcomes of a randomized phase Ⅲ trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage Ⅱ or Ⅲ gastric cancer[J]. J Clin Oncol, 2011, 29(33): 4387-4393. doi: 10.1200/JCO.2011.36.5908
[19]	KAKEJI Y, YOSHIDA K, KODERA Y, et al. Three-year outcomes of a randomized phase Ⅲ trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage Ⅲ gastric cancer: JACCRO GC-07[J]. Gastric Cancer, 2022, 25(1): 188-196. doi: 10.1007/s10120-021-01224-2
[20]	BANG Y J, KIM Y W, YANG H K, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial[J]. Lancet, 2012, 379(9813): 315-321. doi: 10.1016/S0140-6736(11)61873-4
[21]	LEE J, LIM D H, KIM S, et al. Phase Ⅲ trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial[J]. J Clin Oncol, 2012, 30(3): 268-273.
[22]	PARK S H, LIM D H, SOHN T S, et al. A randomized phase Ⅲ trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial[J]. Ann Oncol, 2021, 32(3): 368-374. doi: 10.1016/j.annonc.2020.11.017
[23]	KITANO S, ISO Y, MORIYAMA M, et al. Laparoscopy-assisted billroth I gastrectomy[J]. Surg Laparosc Endosc, 1994, 4(2): 146-148. pmid: 8180768
[24]	KIM H H, HAN S U, KIM M C, et al. Effect of laparoscopic distal gastrectomy vs open distal gastrectomy on long-term survival among patients with stage Ⅰ gastric cancer: the KLASS-01 randomized clinical trial[J]. JAMA Oncol, 2019, 5(4): 506-513. doi: 10.1001/jamaoncol.2018.6727
[25]	KATAI H, MIZUSAWA J, KATAYAMA H, et al. Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage ⅠA or ⅠB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2020, 5(2): 142-151.
[26]	ZENG Y K, YANG Z L, PENG J S, et al. Laparoscopy-assisted versus open distal gastrectomy for early gastric cancer: evidence from randomized and nonrandomized clinical trials[J]. Ann Surg, 2012, 256(1): 39-52. doi: 10.1097/SLA.0b013e3182583e2e
[27]	LIU F L, HUANG C M, XU Z K, et al. Morbidity and mortality of laparoscopic vs open total gastrectomy for clinical stage Ⅰ gastric cancer: the CLASS02 multicenter randomized clinical trial[J]. JAMA Oncol, 2020, 6(10): 1590-1597. doi: 10.1001/jamaoncol.2020.3152
[28]	YU J, HUANG C M, SUN Y H, et al. Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial[J]. JAMA, 2019, 321(20): 1983-1992. doi: 10.1001/jama.2019.5359
[29]	HUANG C M, LIU H, HU Y F, et al. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: five-year outcomes from the CLASS-01 randomized clinical trial[J]. JAMA Surg, 2022, 157(1): 9-17. doi: 10.1001/jamasurg.2021.5104
[30]	HYUNG W J, YANG H K, PARK Y K, et al. Long-term outcomes of laparoscopic distal gastrectomy for locally advanced gastric cancer: the KLASS-02-RCT randomized clinical trial[J]. J Clin Oncol, 2020, 38(28): 3304-3313. doi: 10.1200/JCO.20.01210 pmid: 32816629
[31]	ETOH T, OHYAMA T, SAKURAMOTO S, et al. Five-year survival outcomes of laparoscopy-assisted vs open distal gastrectomy for advanced gastric cancer: the JLSSG0901 randomized clinical trial[J]. JAMA Surg, 2023, 158(5): 445-454. doi: 10.1001/jamasurg.2023.0096
[32]	PARK Y M, CHO E, KANG H Y, et al. The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis[J]. Surg Endosc, 2011, 25(8): 2666-2677. doi: 10.1007/s00464-011-1627-z
[33]	FACCIORUSSO A, ANTONINO M, MASO M D, et al. Endoscopic submucosal dissection vs endoscopic mucosal resection for early gastric cancer: a meta-analysis[J]. World J Gastrointest Endosc, 2014, 6(11): 555-563. doi: 10.4253/wjge.v6.i11.555
[34]	JAPANESE GASTRIC CANCER ASSOCIATION. Japanese gastric cancer treatment guidelines 2010 (ver. 3)[J]. Gastric Cancer, 2011, 14(2): 113-123. doi: 10.1007/s10120-011-0042-4 pmid: 21573742
[35]	JAPANESE GASTRIC CANCER ASSOCIATION. Japanese gastric cancer treatment guidelines 2014 (ver. 4)[J]. Gastric Cancer, 2017, 20(1): 1-19. doi: 10.1007/s10120-016-0622-4 pmid: 27342689
[36]	HASUIKE N, ONO H, BOKU N, et al. A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607)[J]. Gastric Cancer, 2018, 21(1): 114-123. doi: 10.1007/s10120-017-0704-y pmid: 28224238
[37]	JAPANESE GASTRIC CANCER ASSOCIATION. Japanese gastric cancer treatment guidelines 2018 (5th edition)[J]. Gastric Cancer, 2021, 24(1): 1-21. doi: 10.1007/s10120-020-01042-y
[38]	TAKIZAWA K, ONO H, HASUIKE N, et al. A nonrandomized, single-arm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer: Japan Clinical Oncology Group study (JCOG1009/1010)[J]. Gastric Cancer, 2021, 24(2): 479-491. doi: 10.1007/s10120-020-01134-9 pmid: 33161444
[39]	ASSOCIATION J G C. Japanese gastric cancer treatment guidelines 2021 (6th edition)[J]. Gastric Cancer, 2023, 26(1): 1-25. doi: 10.1007/s10120-022-01331-8
[40]	BANG Y J, VAN CUTSEM E, FEYEREISLOVA A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742): 687-697. doi: 10.1016/S0140-6736(10)61121-X
[41]	HECHT J R, BANG Y J, QIN S K, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC: a randomized phase Ⅲ trial[J]. J Clin Oncol, 2016, 34(5): 443-451.
[42]	SATOH T, XU R H, CHUNG H C, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN: a randomized, phase Ⅲ study[J]. J Clin Oncol, 2014, 32(19): 2039-2049. doi: 10.1200/JCO.2013.53.6136
[43]	TABERNERO J, HOFF P M, SHEN L, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study[J]. Lancet Oncol, 2018, 19(10): 1372-1384. doi: S1470-2045(18)30481-9 pmid: 30217672
[44]	THUSS-PATIENCE P C, SHAH M A, OHTSU A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study[J]. Lancet Oncol, 2017, 18(5): 640-653. doi: 10.1016/S1470-2045(17)30111-0
[45]	SHITARA K, BANG Y J, IWASA S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer[J]. N Engl J Med, 2020, 382(25): 2419-2430. doi: 10.1056/NEJMoa2004413
[46]	VAN CUTSEM E, BARTOLOMEO M D, SMYTH E, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study[J]. Lancet Oncol, 2023, 24(7): 744-756. doi: 10.1016/S1470-2045(23)00215-2 pmid: 37329891
[47]	PENG Z, LIU T S, WEI J, et al. A phase Ⅱ study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers[J]. J Clin Oncol, 2020, 38(15_suppl): 4560.
[48]	SHITARA K, LORDICK F, BANG Y J, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial[J]. Lancet, 2023, 401(10389): 1655-1668. doi: 10.1016/S0140-6736(23)00620-7 pmid: 37068504
[49]	SHAH M A, SHITARA K, AJANI J A, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial[J]. Nat Med, 2023, 29(8): 2133-2141. doi: 10.1038/s41591-023-02465-7 pmid: 37524953
[50]	KANG Y K, BOKU N, SATOH T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 390(10111): 2461-2471. doi: 10.1016/S0140-6736(17)31827-5
[51]	JANJIGIAN Y Y, SHITARA K, MOEHLER M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294): 27-40. doi: 10.1016/S0140-6736(21)00797-2 pmid: 34102137
[52]	SHITARA K, ÖZGÜROĞLU M, BANG Y J, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2018, 392(10142): 123-133. doi: S0140-6736(18)31257-1 pmid: 29880231
[53]	BOKU N, RYU M H, KATO K, et al. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase Ⅱ trial (ATTRACTION-4)[J]. Ann Oncol, 2019, 30(2): 250-258. doi: 10.1093/annonc/mdy540
[54]	XU J, JIANG H, PAN Y, et al. LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase Ⅲ study[J]. Ann Oncol, 2021, 32: S1331.
[55]	MOEHLER M H, KATO K, ARKENAU H T, et al. Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC)[J]. J Clin Oncol, 2023, 41(4_suppl): 286.
[56]	RHA S Y, OH D Y, YAÑEZ P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2023, 24(11): 1181-1195. doi: 10.1016/S1470-2045(23)00515-6
[57]	JANJIGIAN Y Y, KAWAZOE A, YANEZ P E, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: initial findings of the global phase 3 KEYNOTE-811 study[J]. J Clin Oncol, 2021, 39(15_suppl): 4013.
[58]	JANJIGIAN Y Y, KAWAZOE A, BAI Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: survival results from the phase Ⅲ, randomized, double-blind, placebo-controlled KEYNOTE-811 study[J]. Ann Oncol, 2023, 34: S851-S852. doi: 10.1016/j.annonc.2023.09.1424
[59]	YUAN S Q, NIE R C, JIN Y, et al. Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: results from a prospective, randomized, open-label, phase Ⅱ trial[J]. J Clin Oncol, 2023, 41(16_suppl): 4001.
[60]	DING X W, WANG X J, LI B, et al. PERSIST: A multicenter, randomized phase Ⅱ trial of perioperative oxaliplatin and S-1 (SOX) with or without sintilimab in resectable locally advanced gastric/gastroesophageal junction cancer (GC/GEJC)[J]. J Clin Oncol, 2023, 41(4_suppl): 364.
[61]	AL-BATRAN S E, LORENZEN S, THUSS-PATIENCE P C, et al. Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: interim results from DANTE, a randomized, multicenter, phase Ⅱb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK[J]. J Clin Oncol, 2022, 40(16_suppl): 4003.
[62]	THRIFT A P, WENKER T N, EL-SERAG H B. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention[J]. Nat Rev Clin Oncol, 2023, 20(5): 338-349. doi: 10.1038/s41571-023-00747-0 pmid: 36959359
[63]	CORDLE F. The use of epidemiology, scientific data, and regulatory authority to determine risk factors in cancers of some organs of the digestive system. 5. Stomach cancer[J]. Regul Toxicol Pharmacol, 1986, 6(2): 171-180. doi: 10.1016/0273-2300(86)90032-2
[64]	ASAKA M. A new approach for elimination of gastric cancer deaths in Japan[J]. Int J Cancer, 2013, 132(6): 1272-1276. doi: 10.1002/ijc.27965 pmid: 23180638
[65]	ASAKA M, KATO M, SAKAMOTO N. Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan[J]. J Gastroenterol, 2014, 49(1): 1-8. doi: 10.1007/s00535-013-0897-8 pmid: 24162382
[66]	CHOI K S, SUH M. Screening for gastric cancer: the usefulness of endoscopy[J]. Clin Endosc, 2014, 47(6): 490-496. doi: 10.5946/ce.2014.47.6.490 pmid: 25505713
[67]	CHEN Z H, LIN L, WU C F, et al. Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine[J]. Cancer Commun, 2021, 41(11): 1100-1115. doi: 10.1002/cac2.v41.11
[68]	JUMPER J, EVANS R, PRITZEL A, et al. Highly accurate protein structure prediction with AlphaFold[J]. Nature, 2021, 596(7873): 583-589. doi: 10.1038/s41586-021-03819-2

Year	TNM staging version
1943-1952	Pierre Denoix proposed TNM staging
1968	UICC version 1
1975	UICC version 2
1977	AJCC version 1
1978	UICC version 3
1983	AJCC version 2
1987	UICC version 4
1988	AJCC version 3
1992	AJCC version 4
1997	UICC/AJCC version 5
2002	UICC/AJCC version 6
2009	UICC/AJCC version 7
2016	UICC/AJCC version 8